AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03599466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zestril Tab 20mg
Description: Zestril Tab 20mg will be used as a reference drug in this study
Study NCT03517293 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise training
Study NCT03028922 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: creos xenogain
Description: GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
Study NCT03061214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.5 mg
Description: Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
Study NCT03061214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1.0 mg
Description: Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
Study NCT03061214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin placebo
Description: Sitagliptin placebo tablets taken once-daily for 30 weeks
Study NCT03061214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg sitagliptin tablets taken once-daily for 30 weeks
Study NCT03061214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide placebo 0.5 mg
Description: Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
Study NCT03061214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide placebo 1.0 mg
Description: Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
Study NCT02427672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study NCT02427672 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Study NCT00967174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: 25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
Study NCT01348490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib (INCB018424), 5 mg bid
Study NCT01623154 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pranactin citric solution
Description: All patients were required to drink the pranactic citric solution to diagnose H.pylori.
Study NCT00967174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
Study NCT00967174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLS Comparator Patch
Description: 0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
Study NCT03874780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibe Delivery system
Description: delivery of Botox (TM) to the bladder wall using an ultrasound technology with the Vibe delivery system
Study NCT00641849 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
Study NCT00641849 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
Study NCT04084782 — intervention group
Intervention type: DEVICE
Intervention: Fungal Nail Treatment Kit
Description: The treatment kit consists of 5 disposable nail files to be used to remove the top layer of the infected nail at various times throughout the use of the product and a liquid formulation and brush applicator.
Study NCT04916899 — intervention group
Intervention type: DRUG
Intervention: Rifampicin/ Isoniazid/ Pyrazinamide/ Ethambutol
Description: Form: Tablets Dosage: 150 mg / 75 mg / 400 mg / 300 mg Adminstration way: Oral
Study NCT03912480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem cells from human exfoliated teeth
Description: Intravenous infusion of pulp mesenchymal stem cells
Study NCT00356486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a, Ribavirin, epoetin-β
Description: Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
Study NCT00356486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a + Ribavirin for 12 weeks
Description: Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
Study NCT02771210 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
Study NCT02771210 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Secukinumab Placebo
Description: Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
Study NCT03316612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vaccinium Myrtillus L. extract
Description: Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study NCT03316612 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
Study NCT02035215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Study NCT02035215 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20mg
Study NCT02035215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-acids ethylesters 90 4g
Study NCT02035215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(Omega-3-acids ethylesters 90)
Study NCT03875547 — intervention group
Intervention type: DRUG
Intervention: Refixia®
Description: Patients will be treated with commercially available Refixia® according to routine clinical practice at the discretion of the treating physician
Study NCT06437691 — intervention group
Intervention type: PROCEDURE
Intervention: Self-Expandable Metallic Stent Placement
Study NCT04292548 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: taking saliva samples to determine TAS, TOS and LL-37
Study NCT00538031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given orally
Study NCT00538031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally
Study NCT00538031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study NCT04042233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Intraosseous vancomycin 500mg in 250 mL NS
Description: 500mg of Vancomycin in 250 mL of normal saline will be injected into a pre-specified region of the greater trochanter during primary total hip arthroplasty.
Study NCT04042233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV administration of vancomycin
Description: IV antibiotics (cefepime \& vancomycin) are started in pre-op approximately 1 hour prior to incision (vancomycin dose weight-based at approximately 15mg/kg, generally 1000-1750mg in 500 mL NS).
Study NCT01894802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of CRS Arrays
Description: Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
Study NCT04018768 — intervention group
Intervention type: OTHER
Intervention: ibuprofen 600 mg
Description: MRN ending in an EVEN # will receive ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN) and oxycodone/acetaminophen (Percocet) 5 mg/325 mg for pain that is not adequately controlled by the ibuprofen.
Study NCT04018768 — intervention group
Intervention type: OTHER
Intervention: Oxycodone/acetaminophen (Percocet) 5 mg/325
Description: MRN ending in an ODD #: will receive the current standard of care postoperative pain management, which is Percocet 5 mg/325 mg every 6 hours PRN.
Study NCT04168411 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Symptomatic Treatment
Description: Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
Study NCT04168411 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symptomatic Treatment
Description: Conservative treatment methods of tuberosity fractures of the proximal fifth metatarsal
Study NCT03068520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET MR
Description: PET MR with 18 Fluorodopa (\[18F\]-DOPA) will be performed on patient at set intervals
Study NCT00098631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study NCT00098631 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00815308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab (Erbitux)
Description: Cetuximab,injection,loading dose400 mg/m\^2,(Day1 in Week1) followed by 250 mg/m\^2(Day1, every week for Weeks 2-8)
Study NCT00815308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel,injection,loading dose 45 mg/m\^2,(Day1 in every week for Weeks 2-8)
Study NCT00815308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin,injection,loading dose 20 mg/m\^2,(Day1 in every week for Weeks 2-8)
Study NCT00815308 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
Study NCT01633060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
Study NCT01633060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Intramuscular fulvestrant 500 mg (Day 1 and Day 15 of Cycle 1 and Day 1 of every cycle thereafter)
Study NCT01633060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 100 mg once daily
Study NCT01633060 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BKM120 matching placebo
Description: BKM120 matching placebo, once daily
Study NCT02902809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab open-label
Description: Subcutaneous injection; fixed dose; 300 mg
Study NCT02066662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban or Marcumar
Description: Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
Study NCT02066662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban or Marcumar
Description: Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;~Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0.
Study NCT02139410 — intervention group
Intervention type: PROCEDURE
Intervention: IGF-1 serum value
Description: Evaluation of IGF-1 serum value at baseline, 24 and 48 months
Study NCT04441866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Standard technique
Description: Standard ultrasound examination without use of automated algorithms for measuring fetal biometry, and for the reconstruction of standard planes of fetal anatomy
Study NCT02937935 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protocol Guided Renal Replacement Therapy
Description: In the on-demand group patients would get dialysis only when patient fulfills absolute criteria requiring dialysis such as metabolic acidosis with ph\<7.2, hyperkalemia, refractory fluid overload (non-responsive to diuretics) or oliguria with urine output of less than 0.5ml/kg for more than 24-48 hours from the time of randomization.
Study NCT02937935 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: On Demand Renal Replacement Therapy
Description: Patients to be randomized to the intervention as per standard of care
Study NCT03793803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Palliative Care
Description: Patients/caregivers will be cared for by an interdisciplinary team that includes a social worker, nurse, community health worker, nurse practitioner, and physician.
Study NCT04273971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric exercises
Description: Plyometric exercises will be composed of vertical jumps, box jumps, half squat jumps, high straight jumps, bounding jumps, drop jumps and 10-m sprint.
Study NCT04061746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSCs)
Description: Patients in Group A will receive a single MSCs infusion
Study NCT04061746 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Infusion (Plasmalyte A with 0.5% human serum albumin)
Description: Patients in Group B will receive a single infusion of placebo (Plasmalyte A with 0.5% human serum albumin)
Study NCT03398486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Dynamic adhesive taping is a method that involves the application of specific tapes to the surface of the patient's skin in order to use the natural self-healing processes of the body. It is often used as an element that sustains the therapeutic effect. Its action is based mainly on the action normalizing muscle tone, supporting the work of joints, improving the function of weakened muscles, increasing microcirculation at the site of application.
Study NCT03398486 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: inactivation of trigger points (TrP)
Description: A procedure for releasing trigger points using physiotherapy using the ischemic compression method, which involves applying pressure to the active trigger point, until it is switched off, i.e. pain ceases.The location of the trigger point is done palpatively, with a pliers grip, covering the strained tissue on the inside and outside of the cheek with the thumb and index finger.
Study NCT00000253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% N2O
Study NCT00000253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20% N2O
Study NCT00000253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30% N2O
Study NCT00000253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40% N2O
Study NCT00421447 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Description: Group of women with breast cancer
Study NCT04746742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneled Femoral Catheter (TFC) group
Description: Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
Study NCT04746742 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoro-femoral Arteriovenous graft (FF-AVG) group
Description: Patients with end-stage chronic kidney disease exhausted upper-extremity and chest-wall vascular accesses will be submitted to creation of a Lower-Extremity Hemodialysis Vascular either through application of tunneled femoral catheter
Study NCT01975987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonfils fiberscope
Study NCT04529187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.
Study NCT04529187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.
Study NCT05313100 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sugammadex
Description: At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
Study NCT05313100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups
Study NCT04024384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab, 16 mg/kg, once a week for 8 weeks (cycles 1 and 2); then every 2 weeks for 16 weeks (cycles 3-6), then every 4 weeks thereafter (cycles 7-12).
Study NCT05544981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: 70 ml of beetroot juice containing \~5 mmol of inorganic nitrate
Study NCT05544981 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot Juice
Description: 70 ml of beetroot juice which is nitrate-depleted
Study NCT03170232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danirixin 35 mg tablets
Description: Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
Study NCT03170232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
Study NCT03170232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metered dose inhaler (MDI) sensor device
Description: MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
Study NCT03170232 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Metered dose inhaler (MDI) sensor device
Description: MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
Study NCT03170232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
Study NCT03170232 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
Study NCT02730897 — intervention group
Intervention type: PROCEDURE
Intervention: Central/Peripheral
Description: Central versus peripheral location of the primary tumor
Study NCT03520244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise + Holistic Education
Description: The exercise group will undertake a 12-week supervised progressive high intensity interval training program supplemented with 6 bi-weekly group-based holistic education sessions.
Study NCT03742908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin/clindamycin
Description: Local implant immersion and/or breast pocket irrigation
Study NCT01439347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposomes Injection (VSLI)
Description: 2.25 mg/m\^2 (without any dose cap) as an IV infusion over 60 minutes.
Study NCT01439347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Injection (VSI)
Description: 1.4 mg/m\^2 with a 2 mg dose cap as an IV infusion over 10 minutes.
Study NCT02607566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Study NCT02607566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise Program
Description: twice weekly aerobic exercise program, 60 minutes for 12 weeks
Study NCT03439527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Precursor Cells (MPCs), ATMP
Description: The advanced therapeutic investigational product, the MPCs, is a living, autologous cell-product isolated from a biopsy of the patient's own musculus soleus.